Euroopa Liit - eesti - EMA (European Medicines Agency)

novo nordisk a/s - aspartinsuliin - diabeet mellitus - diabeetis kasutatavad ravimid - novorapid on näidustatud suhkurtõve raviks täiskasvanutel, noorukitel ja 1-aastastel ja vanematel lastel.

Euroopa Liit - eesti - EMA (European Medicines Agency)

novo nordisk a/s - aspartinsuliin - diabeet mellitus - diabeetis kasutatavad ravimid - suhkurtõve ravi.

Euroopa Liit - eesti - EMA (European Medicines Agency)

novo nordisk a/s - repagliniid - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - repagliniid on näidustatud patsientidele, kelle hüperglükeemia enam juhitavad rahuldavalt dieedi, kehakaalu ja füüsilise tüüp-2 diabeet (mitte-insuliini insuliinsõltumatu suhkurtõbi (niddm)). repagliniid on näidustatud ka kombinatsioonis metformiiniga 2. tüüpi diabeediga patsientidel, kellel ei ole metformiini üksi rahuldavalt kontrollitud. ravi tuleks alustada lisandina toitumise ja treeningu alandada veresuhkru seoses sööki.

Euroopa Liit - eesti - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - immunosupressandid - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) on näidustatud ravi täiskasvanud patsientidel, kellel on varem ravimata hulgimüeloom, kes ei ole abikõlblikud siirdamist. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) on näidustatud ravi täiskasvanud patsientidel, kellel on varem ravimata hulgimüeloom, kes ei ole abikõlblikud siirdamist. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Euroopa Liit - eesti - EMA (European Medicines Agency)

novo nordisk a/s - aspartinsuliin - diabeet mellitus - drugs used in diabetes, insulins and analogues for injection, fast-acting - suhkurtõve ravi täiskasvanutel, noorukitel ja 1-aastastel ja vanematel lastel.

Euroopa Liit - eesti - EMA (European Medicines Agency)

novo nordisk a/s - iniminsuliin - diabeet mellitus - diabeetis kasutatavad ravimid - suhkurtõve ravi.

Euroopa Liit - eesti - EMA (European Medicines Agency)

novo nordisk a/s - repagliniid - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - repagliniid on näidustatud patsientidele, kelle hüperglükeemia enam juhitavad rahuldavalt dieedi, kehakaalu ja füüsilise tüüp-2 diabeet (mitte-insuliini insuliinsõltumatu suhkurtõbi (niddm)). repagliniid on näidustatud ka koos metformiiniga tüüp-2 diabeedi patsientidel, kes on ei saa rahuldavalt reguleerida ainult metformiini. ravi tuleks alustada lisandina toitumise ja treeningu alandada veresuhkru seoses sööki.

Euroopa Liit - eesti - EMA (European Medicines Agency)

novo nordisk a/s - insulin human - diabeet mellitus - diabeetis kasutatavad ravimid - suhkurtõve ravi.

Euroopa Liit - eesti - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; myelodysplastic syndromes; lymphoma, follicular; lymphoma, mantle-cell - immunosupressandid - multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) on näidustatud ravi täiskasvanud patsientidel, kellel on varem ravimata hulgimüeloom, kes ei ole abikõlblikud siirdamist. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 ja 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) on näidustatud ravi täiskasvanud patsientidel, kellel on varem ravimata hulgimüeloom, kes ei ole abikõlblikud siirdamist. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 ja 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Eesti - eesti - Ravimiamet

meda pharma sia - formoterool - inhalatsioonipulber - 6mcg 1annus 60annus 3tk; 6mcg 1annus 100annus 1tk; 6mcg 1annus 60annus 2tk; 6mcg 1annus 60annus 1tk; 6mcg 1annus 100annus 2tk